Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.7150/ijbs.45123

http://scihub22266oqcxt.onion/10.7150/ijbs.45123
suck pdf from google scholar
32226289!7098029!32226289
unlimited free pdf from europmc32226289    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid32226289      Int+J+Biol+Sci 2020 ; 16 (10): 1718-1723
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 #MMPMID32226289
  • Zhou G; Zhao Q
  • Int J Biol Sci 2020[]; 16 (10): 1718-1723 PMID32226289show ga
  • A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2. Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2. Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.
  • |*Betacoronavirus[MESH]
  • |Adaptive Immunity[MESH]
  • |Antibodies, Neutralizing/*therapeutic use[MESH]
  • |Antibodies, Viral/*therapeutic use[MESH]
  • |Antiviral Agents[MESH]
  • |COVID-19[MESH]
  • |COVID-19 Serotherapy[MESH]
  • |Coronavirus Infections/immunology/*therapy[MESH]
  • |Humans[MESH]
  • |Immunity, Innate[MESH]
  • |Immunization, Passive[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/immunology/*therapy[MESH]
  • |SARS-CoV-2[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box